06.03.2012 07:35 Uhr, Quelle: Wallstreet online
MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial
MorphoSys AG / MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Study Data Expected in Q3 …
Weiterlesen bei Wallstreet online
JustMac.info